{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Antonarakis ES"],"funding":["NCI NIH HHS"],"pagination":["4662-4671"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6481607"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["24(19)"],"pubmed_abstract":["<b>Purpose:</b> Sipuleucel-T is FDA approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC) based on the IMPACT trial showing a 4.1-month benefit in median overall survival (OS) for patients receiving sipuleucel-T versus control. Although efficacy of sipuleucel-T is well established, its mechanism remains incompletely understood.<b>Patients and Methods:</b> Patient samples from three sipuleucel-T trials were assessed for peripheral cellular immune responses to the immunogen PA2024 and the target antigen prostatic acid phosphatase (PAP). PAP- and PA2024-specific proliferative and cytolytic responses were characterized to delineate sipuleucel-T-induced immune responses. To quantify potential cytotoxic T lymphocyte (CTL) activity, cell-surface CD107a expression o"],"journal":["Clinical cancer research : an official journal of the American Association for Cancer Research"],"pubmed_title":["Antigen-Specific CD8 Lytic Phenotype Induced by Sipuleucel-T in Hormone-Sensitive or Castration-Resistant Prostate Cancer and Association with Overall Survival."],"pmcid":["PMC6481607"],"funding_grant_id":["P30 CA006973"],"pubmed_authors":["Petrylak DP","Quinn DI","Kibel AS","Campogan D","Dearstyne E","Small EJ","Harmon M","Haynes H","Chang NN","Antonarakis ES","Drake CG","Vu T","Sheikh NA"],"additional_accession":[]},"is_claimable":false,"name":"Antigen-Specific CD8 Lytic Phenotype Induced by Sipuleucel-T in Hormone-Sensitive or Castration-Resistant Prostate Cancer and Association with Overall Survival.","description":"<b>Purpose:</b> Sipuleucel-T is FDA approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC) based on the IMPACT trial showing a 4.1-month benefit in median overall survival (OS) for patients receiving sipuleucel-T versus control. Although efficacy of sipuleucel-T is well established, its mechanism remains incompletely understood.<b>Patients and Methods:</b> Patient samples from three sipuleucel-T trials were assessed for peripheral cellular immune responses to the immunogen PA2024 and the target antigen prostatic acid phosphatase (PAP). PAP- and PA2024-specific proliferative and cytolytic responses were characterized to delineate sipuleucel-T-induced immune responses. To quantify potential cytotoxic T lymphocyte (CTL) activity, cell-surface CD107a expression o","dates":{"release":"2018-01-01T00:00:00Z","publication":"2018 Oct","modification":"2026-05-03T19:31:38.798Z","creation":"2019-06-06T22:48:46Z"},"accession":"S-EPMC6481607","cross_references":{"pubmed":["29858218"],"doi":["10.1158/1078-0432.ccr-18-0638","10.1158/1078-0432.CCR-18-0638"]}}